<DOC>
	<DOCNO>NCT01501617</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy relation dose administration Hair Stimulating Complex ( HSC ) healthy men . HSC inject intradermally scalps men male pattern baldness ( i.e . androgenetic alopecia ) .</brief_summary>
	<brief_title>Safety Efficacy Hair Stimulating Complex ( HSC ) Hair Growth Males With Androgenetic Alopecia</brief_title>
	<detailed_description>HSC consist protein secrete human dermal cell proprietary culture condition include reduce oxygen bioreactors . Under condition , cell secrete soluble protein include growth factor soluble precursor deposit extracellular matrix . Several protein know important control hair cycle stimulate rest hair follicle resume hair formation .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>1 . Male , age 2165 year . 2 . A healthy scalp cutaneous disorder . 3 . Subject good general health . 4 . Male subject must classify 3 Vertex , 4 , 4A ( large enough ) , 5 , 5A , 6 NorwoodHamilton Classification Male Pattern Hair Loss ( See Appendix 1 ) . 5 . Subject must Fitzpatrick Type I , II , III IV skin pigmentation ( See Appendix 2 ) . Type IV acceptable however Type IIII preferable . 6 . Willing able comply schedule visit ( Total : 7 visit 48 week ) 7 . Willing maintain hair style study period . 8 . Willing total four microscopic dot tattoo . Two tattoos per treatment site ( one center one edge ) two target region scalp miniaturization zone . 9 . Willing 2 cm2 hair clip treatment area . 10 . Willing forgo use scalp product , include dye , throughout study except study relate dye . 11 . Willing use mild , nonionic shampoo throughout course study . 1 . History keloid formation hyperpigmentation . 2 . A history acute chronic illness opinion investigator might confound result study include drug medication . 3 . Active skin disease ( e.g . eczema , atopic dermatitis , psoriasis , skin cancer , sun damage skin actinic keratosis scalp , etc. ) . 4 . Routine high dosage use antiinflammatory medication ( aspirin , ibuprofen , corticosteroid ) , immunosuppressive drug antihistamine medication ( steroid nose drop and/or eye drop permit ) . Two 81 mg one 325 mg aspirin per day also acceptable . 5 . Use topical drug cosmetic scalp . 6 . Immunological disorder HIV positive , alopecia areata , systemic lupus erythematosus . 7 . Participation clinical study within last four week . 8 . Moderate severe seborrheic dermatitis scalp . 9 . Damaged skin around test site include sunburn , uneven skin tone , tattoo , scar disfiguration test site . 10 . Use OTC ( overthecounter ) prescriptive topical hair treatment , well hair transplantation surgery last 6 month . This include Minoxidil 2 % 5 % and/or Finasteride 1mg 5alphareductase inhibitor . 11 . Currently use hair system wig . 12 . Presence hair transplant scalp surgery . 13 . History allergy intolerance lidocaine and/or epinephrine . 14 . Use hair dye ( study relate ) study duration . 15 . Any condition Investigator determines subject could place undue risk . 16 . Reported history allergy intolerance bovine protein .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hair Loss</keyword>
	<keyword>Androgenetic Alopecia</keyword>
	<keyword>Baldness</keyword>
	<keyword>Male pattern baldness</keyword>
	<keyword>Male pattern hair loss</keyword>
	<keyword>Hair Regrowth</keyword>
	<keyword>Alopecia</keyword>
	<keyword>Hair growth</keyword>
	<keyword>Regrow Hair</keyword>
</DOC>